PCM
ACOR

Piermont Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Piermont Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-80
Closed -$325K – 208
2014
Q3 		$325K Buy
+80
New +$300K 0.13% 141
2014
Q2 		– Sell
-44
Closed -$202K – 170
2014
Q1 		$202K Buy
+44
New +$178K 0.1% 128

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Piermont Capital Management's ACOR Position: Q4 2014 in Review

Piermont Capital Management sold out of Acorda Therapeutics (ACOR) in Q4 2014, closing a stake of 80 shares — an estimated $325K sold.

Piermont Capital Management first reported a position in ACOR in Q1 2014 and held it in 2 quarters. The position peaked at $325K in Q3 2014. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2014.

  • Piermont Capital Management reported no remaining Acorda Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Piermont Capital Management sold 80 Acorda Therapeutics shares in Q4 2014, an estimated $325K.
  • Piermont Capital Management first reported a position in Acorda Therapeutics in Q1 2014 and held it in 2 quarters.
  • Piermont Capital Management's Acorda Therapeutics position peaked at $325K in Q3 2014.
  • 179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2014.

Based on Piermont Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.